For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Prime Medicine Inc (NASDAQ: PRME) closed at $3.64 up 1.11% from its previous closing price of $3.6. In other words, the price has increased by $1.11 from its previous closing price. On the day, 16.39 million shares were traded. PRME stock price reached its highest trading level at $3.8499 during the session, while it also had its lowest trading level at $3.61.
Ratios:
For a deeper understanding of Prime Medicine Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.61 and its Current Ratio is at 6.61. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.68.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 01 ’25 when GV 2021 GP, L.L.C. bought 1,500,000 shares for $3.30 per share. The transaction valued at 4,950,000 led to the insider holds 3,262,440 shares of the business.
NELSEN ROBERT bought 3,030,300 shares of PRME for $9,999,990 on Aug 01 ’25. The Director now owns 6,230,300 shares after completing the transaction at $3.30 per share. On Aug 01 ’25, another insider, ARCH Venture Partners XII, LLC, who serves as the 10% Owner of the company, bought 3,030,300 shares for $3.30 each. As a result, the insider paid 9,999,990 and bolstered with 6,230,300 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 657058816 and an Enterprise Value of 549266752. For the stock, the TTM Price-to-Sale (P/S) ratio is 109.88 while its Price-to-Book (P/B) ratio in mrq is 4.06. Its current Enterprise Value per Revenue stands at 91.897 whereas that against EBITDA is -2.791.
Stock Price History:
The Beta on a monthly basis for PRME is 2.70, which has changed by 0.29537368 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, PRME has reached a high of $6.94, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -16.02%, while the 200-Day Moving Average is calculated to be 12.23%.
Shares Statistics:
For the past three months, PRME has traded an average of 3.87M shares per day and 4477820 over the past ten days. A total of 180.31M shares are outstanding, with a floating share count of 93.82M. Insiders hold about 48.03% of the company’s shares, while institutions hold 38.15% stake in the company. Shares short for PRME as of 1764288000 were 19673466 with a Short Ratio of 5.08, compared to 1761868800 on 18214907. Therefore, it implies a Short% of Shares Outstanding of 19673466 and a Short% of Float of 17.78.
Earnings Estimates
A comprehensive evaluation of Prime Medicine Inc (PRME) is underway, with the input of 11.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.11 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.09 and -$1.41 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$0.9, with 10.0 analysts recommending between -$0.56 and -$1.39.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for PRME’s current fiscal year. The highest revenue estimate was $13.79M, while the lowest revenue estimate was $3.79M, resulting in an average revenue estimate of $5.7M. In the same quarter a year ago, actual revenue was $2.98M
